After its own vaccine flop, CureVac sues Pfizer partner BioNTech for patent infringement

A year after a high-profile flop with its COVID-19 vaccine candidate, CureVac is still trying to get a piece of the action.

On Monday, the company revealed that it is suing fellow German mRNA pioneer BioNTech for infringement of its intellectual property by developing the Pfizer-partnered COVID shot Comirnaty.